NCT05068440 2026-03-25Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibBeOne MedicinesPhase 2 Completed65 enrolled 14 charts
NCT03336333 2026-03-09SEQUOIABeOne MedicinesPhase 3 Active not recruiting590 enrolled 12 charts 2 FDA
NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts